Curalin well tolerated and notably improves HbA1c in diabetes patients
Israel: Curalin supplementation in patients with type 2 diabetes is well-tolerated and significantly reduced haemoglobin A1C (HbA1c) for one month, a recent study published in Diabetes/Metabolism Research and Reviews.
Type 2 diabetes is caused when the body either resists insulin or is produced insufficiently. The condition leads to high blood sugar levels, which can damage the organs and cause other complications. There is no cure for the state; however, many people can manage their blood sugar levels with exercise, diet and medication.
A balanced, nutritious diet, physical activity, and maintaining a moderate weight are the first and sometimes the most important parts of diabetes management. However, taking certain herbs and supplements may provide additional benefits.
CuraLin is a 100% natural glucose support supplement for people looking to control their blood sugar levels and enjoy life. It combines ancient Ayurveda practices with modern science and technology into a spectacular, synergistic glucose support formula.
Each capsule of Curalin is manufactured close to the source using only premium ingredients. Secret production processes ensure that each capsule is safe and potent. Independent quality controls ensure that only the best, highest-quality supplements are delivered. CuraLin comprises nine natural ingredients.
Roni Weinberg Sibony from the Hebrew University of Jerusalem in Jerusalem, Israel, and colleagues aimed to examine the safety and efficacy of Curalin supplement in patients with type 2 diabetes.
The study included adult patients with type 2 diabetes. They were randomized in a ratio of 1:1 to receive a Curalin supplement or placebo. HbA1c decrease at one month was determined (primary endpoint). The secondary endpoint was HbA1c reduction by more than 0.5% and 1% and a change in seven daily blood glucose measurements. A satisfaction questionnaire was used as an exploratory endpoint. Adverse events and safety variables were assessed.
The researchers reported the following findings:
- After one month of intervention, HbA1c was reduced by 0.94% in the Curalin arm vs. 0.4% in the placebo arm.
- 72% of Curalin patients had decreased HbA1c levels >0.5% versus 35% in the placebo arm.
- The treatment Satisfaction Questionnaire indicated that Curalin arm patients reported higher overall satisfaction.
"Curalin treatment in patients with type 2 diabetes significantly reduced HbA1c over one month and was well tolerated," the researchers conclude.
Reference:
Sibony RW, Wainstein J, Shalom MI, Ganz T, Rozenberg A, Yanuv I, Eliyahu U, Raz I. Curalin Supplement for Patients with Type 2 Diabetes Mellitus. Diabetes Metab Res Rev. 2023 Feb 16:e3624. doi: 10.1002/dmrr.3624. Epub ahead of print. PMID: 36797773.
